Allogeneic Hematopoietic Cell Transplantation in Pediatric MDS Including Refractory Cytopenia of Childhood and in Juvenile Myelomonocytic Leukemia

Abstract

AbstractPediatric MDS can be associated with germline predisposition, related to cytotoxic or immunmodulatory therapy, or occurs as de novo disease. SCT strategy is primarily dependent on blast count, karyotype, molecular abberrations, and BM cellularity. Juvenile myelomonocytic leukemia is a very heterogenous disease, not all children require SCT. Risk factors for relapse following SCT include age, HbF level, presence of secondary mutations and DNA methylation class.